Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation

Bone Marrow Transplant. 2022 May;57(5):840-842. doi: 10.1038/s41409-022-01633-6. Epub 2022 Mar 10.

Authors

Toshiyuki Ueno¹, Takanori Ohta², Yasuhiro Sugio², Yuju Ohno², Yasufumi Uehara²

Affiliations

¹ Department of Hematology, Kitakyushu Municipal Medical Center, Fukuoka, Japan. toshi.u.57@gmail.com.
² Department of Hematology, Kitakyushu Municipal Medical Center, Fukuoka, Japan.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Lung Diseases, Interstitial* / etiology
Lung Diseases, Interstitial* / therapy
RNA, Messenger
Vaccination

Substances

COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine